Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls.
OBJECTIVE
To compare the effectiveness of weekly vs daily iron and folic acid supplementation for control of anemia in adolescent Nepalese girls.


METHODS
Randomized controlled trial.


METHODS
A Government Girl School in Dharan, Nepal, an urban foothill town that is 305 m above sea level.


METHODS
Consecutive healthy adolescent girls (n = 209, median age 15 years) randomized to 3 groups matched for age, anthropometry, and personal and sociodemographic characteristics. Of 209 subjects, 181 completed the trial. Two girls had adverse reactions to treatment and were excluded.


METHODS
Group A (n = 70) received a 350-mg ferrous sulfate and 1.5-mg folic acid combination once daily for 90 to 100 days. Group B (n = 67) received the tablet under supervision once a week for 14 weeks. Group C (n = 72) did not receive any drugs.


METHODS
Presupplementation and postsupplementation differences in prevalence of anemia and change in hematocrit.


RESULTS
Prevalence of anemia (defined as hematocrit <36%) declined from 68.6% and 70.1% in groups A and B to 20% and 13.4%, respectively, postsupplementation (P<.001), whereas the prevalence in group C changed little (68.1% to 65.3%, P =.81). There was a significant rise in the mean hematocrit of both supplemented groups (group A, 32.9% +/- 3.5% to 41.0% +/- 5.6%, P<.001; group B, 33.2% +/- 3.6% to 40.4% +/- 4.9%, P<.001) but no appreciable change in controls (34.2% +/- 2.9% to 34.1% +/- 3.3%, P =.91). Net change in mean hematocrit in both the supplementation groups was comparable (P =.57).


CONCLUSIONS
The prevalence of anemia in adolescent Nepalese girls is high. Supervised iron and folic acid therapy once a week is an effective alternative to daily administration and helps lower the prevalence of anemia in adolescent girls.
Shah
Binay Kumar
BK
Department of Pediatrics, B. P. Koirala Institute of Health Sciences, Dharan, Nepal.
Gupta
Piyush
P
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D009390:Nepal / Q000453:epidemiology; D015995:Prevalence
D005296:Ferrous Compounds; D006397:Hematinics; C020748:ferrous sulfate; D005492:Folic Acid